You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Product menu

Stringent manufacturing processes ensure that every dose of Augmentin you prescribe fights infections relentlessly

According to the WHO, poor quality antibiotics may lead to treatment failure and drive the development of antimicrobial resistance.1,2

Since its inception 40 years ago, Augmentin has committed to constant innovation to bring you high-quality amoxicillin-clavulanate.3

Augmentin assures constant innovation that responds to clinical experience, customer needs and the commitment to fight antimicrobial resistance

Foil packaging designed with the
right land space size to maintain
the optimal moisture and stability
of the highly sensitive formulation4

The science of maintaining
critical balance when combining amoxicillin and clavulanic acid
honed into an art form4

Evolving amoxicillin: clavulanic
acid ratios to help overcome resistance and manage
severe infections5

Augmentin adheres to stringent processes that ensure that a reliable antibiotic reaches your patients

Maintaining stability of critical ingredients

  • Precise processes that maintain the optimal conditions for combining amoxicillin and clavulanic acid5
  • Temperature controlled shipping of clavulanic acid sourced from single site in Irvine, Scotland7

Exacting standards
 

  • 140 dedicated experts6
  • 300 stability tests for select batches6

 

 

Assured product
 

  • GSK’s QMS which conforms to all worldwide regulatory expectations4
  • Integrated anti-counterfeiting measures and packaging in sealed pouches8,9
     

 

 

Need help with this product?

Request a contact

Need help

Stay Informed

Prescribing Information

References

  1. Nwokike, J., Clark, A. & Nguyen, P.P. Medicines quality assurance to fight antimicrobial resistance. Bulletin of the World Health Organization 96, 135-137 (2018).
  2. Pisani E. Antimicrobial resistance: What does medicine quality have to do with it? Review on Antimicrobial Resistance. [Internet] November 2015 [cited 26 July, 2021]. Available from: https://amr-review.org/sites/default/files/ElizabethPisaniMedicinesQualitypaper.pdf.
  3. European Medicines Agency. Scientific conclusions and grounds for amendment of the summaries of product characteristics, labelling and package leaflet presented by the EMEA. [Internet] 2008. [Cited 5 September 2021]. Available from: https://www.ema.europa.eu/en/documents/referral/augmentin-article- 30-annex-ii_en.pdf.
  4. GSK. Data on file 2023N538816_00. August 2023.
  5. White AR, et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004;53 Suppl 1:i3-20.
  6. GSK. Data on file. 2019N396004_00. January 2019.
  7. GSK. Data on file. 2019N419945_00. September 2019.
  8. GSK. GSK Policy Decisions. The Counterfeiting of Healthcare Products. [Internet] June 2022 [cited 22 January 2024]. Available from: https://www.gsk.com/media/8837/gsk-position-on-falsified-and-substandard-healthcare-products-june-2022.pdf.
  9. Augmentin Amoxicillin + clavulanic acid BD tablets. Jamaica Prescribing Information. Version number: GDS26/IPI13.

Prepared by GSK. For adverse events reporting or product complaints contact GSK by email fv.aecaricam@gsk.com or phone : Jamaica +1(876) 630-2074.
GSK Offices, Oceania Business Plaza Torre 1000 floor 34. Panama, Republic of Panama, C.A. All rights reserved GSK. The complete prescribing information and/or reference are available upon request. Trade marks are owned by or licensed to the GSK group of companies. Material Exclusive for Healthcare Professionals.

Augmentin is a registered trademark of the GlaxoSmithKline group of companies.

PM-RCH-ACA-WCNT-230005 | Approval date: January 2024. Expiration date: January 2026